If he could see himself now, Harry would be horrified. Slack-mouthed, out for the count, he has got drips going into him, tubes coming out of him, wires and sensors everywhere you look. And now the final indignity: Someone is taking the clippers to that rich, golden fur.
“Poor thing,” a nurse says. “He isn’t half going to look weird.”
There is worse to come. A neurosurgeon called Patrick Kenny is about to insert two stainless-steel pins into Harry’s skull. To these he will fit a clamp, immobilizing Harry’s head. His jaws will be wedged open. Then Kenny will cut a tiny hole through the back of the roof of Harry’s mouth and, in an operation that will last more than four hours, set about removing a pea-sized tumor from a vital gland at the base of his brain.
Harry is a cat. A 12-year-old maine coon. He is a big old fella, as maine coons generally are, but Harry is considerably bigger than he should be, because the tumor on his pituitary gland is causing it to produce far more growth hormone than it should, a condition known as acromegaly. This has led to one of the disease’s most common complications — uncontrolled diabetes, as the excess hormone counters the effects of insulin.
So Harry has needed insulin injections, and lots of them: 12 units, morning and night. It is miserable and according to Harry’s owners, Richard and Tracy Mills, it is not making any appreciable difference. The options are not plentiful, says Stijn Niessen, a lecturer in internal medicine at the Royal Veterinary College’s Queen Mother Hospital for Animals (QMHA) near Potters Bar, England.
“You can continue controlling the diabetes with insulin, but that’s a bit like mopping the floor with the tap turned on,” Niessen says, as eight vets and nurses in surgical scrubs busy themselves purposefully around Harry, flat out on the table. “The tumor continues to grow slowly — but there will eventually be a neurological impact.”
There is radiation therapy, but that is long and tough: between five and 10 sessions, each requiring a general anesthetic and with no guarantee of success. There are also drugs called somatostatins, which inhibit the growth hormone, “but they’re not generally very useful, at least not in cats.”
Or there’s this operation: “Which is, well ... rather new.”
In fact, it has been done a bare handful of times and only once before in Britain — at the QMHA. The risk, Niessen says, is very real: Harry could die.
“But the owners were of the opinion that it was better to attempt it,” he says. “Not doing so would mean the tumor getting worse, Harry continuing to live with uncontrollable diabetes and his quality of life being very poor — and deteriorating. And that’s what it’s about: quality of life for the animal. That’s why we do this. That’s why we’re here.”
Some people, of course, will question whether it is right for a shining, state-of-the-art institution like the QMHA, perhaps the finest of its kind in the world — open round the clock, 365 days a year, employing 200-plus highly qualified staff, with spacious consulting rooms, cutting-edge operating theaters, the latest in ECG, CT and MRI equipment, a hydrotherapy tank and even a blood donor program — to be devoted to treating pet cats and dogs (“companion animals” is now the preferred term).
The QMHA treats up to 8,000 patients a year, most referred by their vets, for every conceivable condition: from acute heart failure to advanced neuromuscular disorders, malignant tumors to gastrointestinal disease, joint replacements to epilepsy. The array of disciplines offered here is as complete as anyone could want: anesthesia, cardiology, dermatology, emergency and critical care, internal medicine, neurology, oncology, opthalmology, orthopaedics, soft-tissue surgery, says Holger Volk, genial head of the hospital’s small animal group.
To the uninformed visitor, it does indeed look more like a plush private healthcare facility for wealthy, or at least well-insured, humans. At reception, the only giveaway — in the temporary absence of any pets — is a polite, but one imagines, vitally important notice: “To ensure the safety of all patients, we would ask our clients to keep cats in their baskets and dogs on leads at all times.”
This is plainly not an argument likely to be settled any time soon. Suffice it to say you will not find anyone here, staff or owner, who does not believe absolutely, like Niessen, that if an operation like the one now being performed on Harry can win the patient even a year or two of real quality of life, it is worth the £3,000-odd (US$4,794) it will end up costing his owners’ insurance company (some bills can be nearly twice as high).
However, there is another good reason for doing this particular operation.
“What’s fascinating is that this disease is quite rare in humans, but quite prevalent in cats,” Niessen says. “And we still don’t know what causes these tumors. Are there genetic factors? So these tumor cells will be cultured and researchers will try to find out what’s gone wrong with the gland. This operation could change the way we deal with this disease in people.”
The concept of “one medicine” or “one health” — the idea that human and veterinary medicine are not divided, but can and should complement each other — is not new. Such giants of the profession as Rudolf Virchow, known as the father of modern pathology, and Sir William Osler, a founding professor at Johns Hopkins Hospital and considered the inventor of modern medical teaching, both preached it, eloquently, in the 19th century.
However, although a number of diseases are shared by humans and animals, the concept has only lately begun to gain traction, spurred in particular by the similarities discovered recently between the gene profiles of humans and many animals. In 2007, the American Veterinary Medicine Association launched a drive “to unite human and veterinary medicine to improve animal and public health,” while in Britain the Wellcome Trust is now funding five years of research at Imperial College into the historical convergences between human and animal medicine.
Niessen believes the communities can learn from each other.
“Around 80 percent of diabetic cats have Type 2 diabetes — the condition that’s costing the UK health service £1 million an hour,” he says. “There are similarities between inflammatory bowel diseases in dogs and Crohn’s disease, and between Cushing’s disease and hyperthyroidism in cats. Cancers: lymphoma, leukemia. I could name you 100 diseases humans and animals share, and the list would not be complete.”
Human medicine puts “a lot of money and effort into trying to replicate these diseases, in mice for example,” Niessen says. “That can certainly help, but at best they’re basically models — not the naturally occurring disease. And yet in cats and dogs, we have those very diseases, occurring naturally.”
Some very respected human medics are already persuaded of the possible benefits of a more integrated — or at least a more collaborative — approach. Niessen works with James Shaw, professor of regenerative medicine for diabetes at the University of Newcastle. He says doctor-vet collaboration is “only touching the surface at the moment” and could potentially prove “really very exciting.”
Shaw says regenerative medicine — cell and tissue transplantation, gene therapy — in pets holds enormous promise, both in the benefits it can offer patients and in the development of therapies that may also work with humans.
Rodents are not so helpful.
“What we see in mice isn’t necessarily the same as what we see in humans,” he says.
Cats and dogs, on the other hand, look “much more like human patients. It’s becoming increasingly clear that the diseases are very similar. And whereas regulations are just as stringent as for a regenerative medicine trial on a person, with companion animals it’s more acceptable, simply because the risk-benefit is different,” he says.
Not that this is “a cheap and cheerful way of doing animal testing,” he adds. “You’re talking about real utility and benefit to an animal with a relatively short life who is unwell — just like a human. The benefits to these animals will be there, clinically.”
Hopefully, they will be for Harry. Kenny, the neurosurgeon, is now well into his operation, working with fierce precision, aided by a computer monitor displaying data and images from a prior CT scan of Harry’s brain. Niessen, manning the IV lines, is “the hormone man.”
“We’re removing a tumor from an essential gland here. Harry will need cortisone infused, his glucose levels could be an issue, salt and water will be really important ... The potential for the patient to become unstable is very high,” he says.
For most of the owners whose animals are treated here, “one medicine” means little. They are simply devoted to their pets and want them to get better.
Nigel and Ros Gale from Whitstable have brought their seven-year-old German shepherd for a checkup after surgery six weeks ago; Max has a serious immune-system disorder.
“There’s no cure,” Nigel says. “It’s about maintenance now.”
The couple are uninsured and have spent £6,000 on their dog since he first fell ill.
“But what is the alternative?” Nigel asks. “I certainly don’t see one.”
Darren and Margaret Mangan from Uxbridge feel the same about Charlie, a three-year-old springer spaniel. Charlie very nearly died earlier this year.
“Bleeding from his spinal cord, lost the use of back legs,” Darren says. “Platelet count was at zero. Blood oozing from every orifice. He was put on steroids and they did his immune system in. Attacked his prostate, liver, kidneys.”
After two weeks at the QMHA — and a bill of £5,500 — Charlie is now pretty much himself again. The Mangans, thankfully, were insured (“Best £12 a month I ever spent,” Darren says).
However, “even if we hadn’t been, you’d have to have paid. I can’t understand people who don’t. He’s just such a lovely fellow. Our best mate. You couldn’t ever get rid of him,” he says.
Like every owner I meet, Collette Parker, whose cat Henry has been hit by cars twice in 10 months, is beyond grateful to the hospital and its staff.
“They’re just brilliant,” she says. “They call every day, even late in the evening, to keep you posted. They really, really care. Henry’s had his leg pinned, he’s had a bone graft, he’s got an external leg frame. I think they must send the staff on a special cat-whispering course. They’re just amazing.”
They come from around the world to work here. Clinical veterinary medicine in Britain is recognized as pretty much the best there is (there are almost as many specialists working here as in the whole of the rest of Europe), but this hospital in particular is seen as “exceptional,” says neurologist Birgit Parzefall, who has finally made it — after three attempts — to the QMHA from her native Germany.
Stefano Cortellini from Rome, working in emergency and critical care, says it’s “right at the top of everyone’s list.”
They come here because “they want to make things better,” Niessen says. “Make untreatable illnesses treatable, and treatable illnesses curable.”
Most could probably earn more elsewhere: The QMHA is self-financing and not for profit.
“I earn half what I could make in some places,” Volk says frankly, watching two nurses take Alfie, a dachshund recovering from major spinal surgery to correct a disc problem, for a walk down the corridor in a supporting sling. “But people come, and stay, because it’s cutting-edge. We’re advancing veterinary science.”
There is little doubt of that as far as Harry is concerned. A week after the operation, I speak to his owners. The couple are insured and did not think long about having the operation.
“It’s about quality of life,” Tracy says. “He wouldn’t have had much without it. And if it can benefit other cats, and even maybe humans, then so much the better.”
Did it work?
“He’s fine,” Tracy says. “He’s eating more moderately and his character’s starting to come back. If you put your head down, on his level, he’ll give you this affectionate little head-butt, like he used to.”
More importantly, Richard says, the diabetes appears to have gone.
“Harry’s blood-sugar level seems to be at the right level and he hasn’t needed any insulin since the operation. None. It’s been a complete success,” he says.
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
Former president Ma Ying-jeou’s (馬英九) trip to China provides a pertinent reminder of why Taiwanese protested so vociferously against attempts to force through the cross-strait service trade agreement in 2014 and why, since Ma’s presidential election win in 2012, they have not voted in another Chinese Nationalist Party (KMT) candidate. While the nation narrowly avoided tragedy — the treaty would have put Taiwan on the path toward the demobilization of its democracy, which Courtney Donovan Smith wrote about in the Taipei Times in “With the Sunflower movement Taiwan dodged a bullet” — Ma’s political swansong in China, which included fawning dithyrambs